# Greek NIS Spiolto ELLACTO

> **NCT03419962** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1360 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** MaxSpiolto® Respimat® 160 Characters...

## Key facts

- **NCT ID:** NCT03419962
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-19
- **Primary completion:** 2018-11-09
- **Final completion:** 2019-04-03
- **Target enrollment:** 1360 (ACTUAL)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419962, "Greek NIS Spiolto ELLACTO". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03419962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*